You are here

New Formulation of Fenofibrate Cleared by FDA

ALPHARETTA, Ga.--(BUSINESS WIRE)--May 9, 2005--First Horizon Pharmaceutical(R) Corporation (Nasdaq:FHRX) today announces that the US Food and Drug Administration ("FDA") has approved Triglide, its new fenofibrate formulation. Triglide will be administered in two strengths - 160 mg and 50 mg. Triglide will be manufactured and supplied by SkyePharma PLC (Nasdaq: SKYE; LSE: SK) in accordance with the existing Agreement.

First Horizon retained exclusive US marketing rights in May 2004 to fenofibrate IDD-P, a novel fenofibrate formulation that employs one of SkyePharma's proprietary solubilization technologies. Under its Agreement with SkyePharma, First Horizon will make a payment of $15 million to Skye as a result of the approval. First Horizon will also pay royalties and sales-based milestone payments to SkyePharma and SkyePharma will make a contribution of up to $5 million to First Horizon's initial marketing expenses to establish Triglide.

Triglide is an oral treatment for lipid disorders such as elevated cholesterol (hypercholesterolemia) and triglycerides (hypertriclyceridemia). Triglide can be administered under fed and fasting conditions yielding a comparable extent of absorption and therefore allows patients to take the drug at any time, contributing to improved compliance.

Source: First Horizon Pharmaceutical Corporation

Recent Headlines

One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment
Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids